Stocks That Hit 52-Week Lows On Friday
During Friday's session, 574 stocks hit new 52-week lows.
Peering Into NexImmune’s Recent Short Interest
NexImmune's (NASDAQ:NEXI) short percent of float has fallen 20.71% since its last report. The company recently reported that it has 475 thousand shares sold short, which is 2.45% of all regular shares that are available for trading.
NexImmune Shares Jump On Immunotherapy Pact For Rare Cancers, Autoimmune Disorders
Selexis SA and NexImmune Inc (NASDAQ:NEXI) have agreed to develop cell lines targeting rare cancers and autoimmune diseases and to advance two HLAs…
Selexis and NexImmune Sign Service Agreement To Advance Multiple Immunotherapies Targeting Rare Cancers And Autoimmune Disorders
Selexis SA, a JSR Life Sciences company, and NexImmune Inc. (NASDAQ:NEXI), a clinical-stage biotechnology company developing unique approaches to T cell immunotherapies, announced today that they have signed a service
NexImmune Pauses Developing Multiple Myeloma Hopeful, Citing Competition
NexImmune Inc (NASDAQ: NEXI) cited the competitive environment in the blood cancer space as the reason for
NexImmune Price Target Cut By 75%, Plus Wells Fargo Lowers PT Price Target On These Stocks
Raymond James cut the price target for NexImmune, Inc. (NASDAQ: NEXI) from $12 to $3. NexImmune shares rose 2.4% to $1.29 in pre-market trading.
Raymond James Maintains Outperform on NexImmune, Lowers Price Target to $3
Raymond James analyst Steven Seedhouse maintains NexImmune (NASDAQ:NEXI) with a Outperform and lowers the price target from $12 to $3.
Recap Of Monday’s Biotech Catalysts – End Of the Day Summary
Gritstone bio (NASDAQ:GRTS) announced that interim results from the Phase 1/2 trial of GRANITE, its individualized, vaccine-based immunotherapy…
NexImmune Q2 EPS $(0.69) Down From $(0.54) YoY
NexImmune (NASDAQ:NEXI) reported quarterly losses of $(0.69) per share. This is a 27.78 percent decrease over losses of $(0.54) per share from the same period last year.